depot leuprolide acetate

Phase 3Small molecule

JJoseph Mccune

depot leuprolide acetate is one of 55 small molecule programs targeting Rheumatic Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseActive, not recruiting

Rheumatic DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Rheumatic Disease

#DrugCompanyPhaseTrials

Anjeso

Boehringer Ingelheim

Approved

1 2

Oruvail

WWyeth-Lederle Vaccines

Approved

—3

Bextra

TThe Searle Company Limited Pakistan

COVID-19 Vaccine

2 5

Jascayd

Ilaris

1 7

Orencia

Bristol-Myers Squibb

Phase 2

1 8

Cosentyx

Novartis

Phase 2

1 9

Taltz

Eli Lilly

Phase 2

1 10

Bimzelx

UCB

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatic Disease1 trial

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

Terminated·JJoseph Mccune·Phase 3·NCT01257802·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for depot leuprolide acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — depot leuprolide acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for depot leuprolide acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Joseph Mccune company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJoseph Mccune

depot leuprolide acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatic Disease1 trial

References

Drug Info

Quick Facts

Related News